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ABSTRACT
Granulin-epithelin precursor (GEP) has been demonstrated to confer enhanced 
cancer stem-like cell properties in hepatocellular carcinoma (HCC) cell line models in 
our previous studies. Here, we aimed to examine the GEP-expressing cells in relation 
to the stem cell related molecules and stem-like cell properties in the prospective 
HCC clinical cohort. GEP protein levels were significantly higher in HCCs than the 
paralleled non-tumor liver tissues, and associated with venous infiltration. GEPhigh 
cells isolated from clinical HCC samples exhibited higher levels of stem cell marker 
CD133, pluripotency-associated signaling molecules β-catenin, Oct4, SOX2, Nanog, 
and chemodrug transporter ABCB5. In addition, GEPhigh cells possessed preferential 
ability to form colonies and spheroids, and enhanced in vivo tumor-initiating ability 
while their xenografts were able to be serially subpassaged into secondary mouse 
recipients. Expression levels of GEP and pluripotency-associated genes were further 
examined in the retrospective HCC cohort and demonstrated significant correlation 
of GEP with β-catenin. Notably, HCC patients with high GEP and β-catenin levels 
demonstrated poor recurrence-free survival. In summary, GEP-positive HCC cells 
directly isolated from clinical specimens showed β-catenin elevation and cancer stem-
like cell properties.
INTRODUCTION
Tumor heterogeneity has long been explained by 
clonal evolution of tumor cells resulting from progressive 
accumulation of numerous genetic or epigenetic changes 
[1, 2]. However, recent studies have suggested that such 
heterogeneity results from the hierarchical organization 
of tumor cells with a subset of cells called cancer stem 
cells (CSCs) lying at the apex of the hierarchy [3]. The 
proposed concept of cancer as an abnormal stem cell 
disease was based on the similarities of cancer cells and 
normal stem cells to self-renew and produce heterogeneous 
progenies [4]. CSCs are highly tumorigenic, resistant to 
conventional therapies, and are responsible for tumor 
relapse [5]. The presence of CSCs has been reported in 
diverse malignancies including breast [6], colon [7] and 
liver cancers [8, 9]. Although advances have been made 
in hepatic CSC identification, precise origin of these cells 
and the underlying regulatory mechanism remain unclear.
Granulin-epithelin precursor (GEP) is a pluripotent 
growth factor regulating early fetal development, adult 
tissue repair, inflammation and tumorigenesis [10]. Our 
group has demonstrated over-expression and tumorigenic 
role of GEP in HCC [11–15]. GEP blockage using anti-
body effectively sensitized HCC cells to chemotherapeutic 
agents and inhibited the growth of established HCC 
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xenografts [14, 16]. Recently, we revealed that GEP was 
a hepatic oncofetal protein regulating hepatic cancer 
stem cell (CSC) properties [17] and rendering HCC cells 
resistant to NK cytotoxic activity [18]. Interestingly, GEP 
was shown to regulate the expression of pluripotency-
associated signalling molecules β-catenin, Oct4, Nanog 
and SOX2 in HCC cell lines [17].
Wnt signaling pathway is crucial for self-renewal 
and proliferation of stem cells in various tissues [19]. 
β-catenin protein, encoded by the CTNNB1 gene, is the 
central player in canonical Wnt pathway. β-catenin can 
be found in several cellular compartments, including the 
inner plasma membrane, cytoplasm and nucleus [20]. 
Upon activation, cytoplasmic β-catenin accumulates 
and translocates into nucleus, where it forms an active 
complex containing T-cell factor/lymphoid enhancer 
factor transcription factors that induces the expression 
of its target genes [21]. Wnt pathway is activated in 
various types of cancer constitutively, leading to cell 
reprogramming and stem-like phenotype [22, 23]. 
β-catenin activation has been observed in different 
hepatic CSC subpopulations such as CD133+, EpCAM+, 
and GEP+ cells and might play role in maintaining the 
hepatic CSC features [9, 17, 24, 25]. Aberrant Wnt/β-
catenin signaling by mutational and non-mutational 
events is observed in around one third of HCCs, implying 
the significance of this pathway in hepatocarcinogenesis 
[26]. In fact, deregulation of Wnt/β-catenin signaling is 
involved in early hepatocarcinogenesis and is associated 
with aggressive features of HCC, due to its role in cell 
survival, proliferation, migration and invasion [21, 27].
In this study, we characterized the CSC properties 
of GEP-expressing cells in the prospective HCC 
clinical cohort, and elucidated the underlying molecular 
mechanism with respect to the stem cell-related signaling 
molecules. These have been further substantiated in the 
retrospective HCC cohort.
RESULTS
GEP positive HCC cells in clinical specimens 
exhibit cancer stem cell phenotype
HCC and paralleled non-tumor liver tissues from 90 
patients were freshly collected. After single cell isolation, only 
HCCs with high cell viability (viability ≥ 70%) were subject to 
subsequent phenotypic characterization and functional assays. 
A total of 42 HCCs (47%) generated cells with high viability. 
Importantly, HCCs with high cell viability were significantly 
associated with presence of venous infiltration, poorly-
differentiated tumors and high AFP levels (Supplementary 
Table S1). Therefore, the more aggressive subset of HCCs 
were able to tolerate the single-cell isolation procedure for 
subsequent functional experiments.
Previously, our group has demonstrated by RT-
qPCR and immunohistochemistry that GEP levels were 
significantly elevated in HCC when compared with 
paralleled adjacent non-tumor liver tissues [11, 13]. Here, 
the GEP protein expressions have been quantified by 
flow cytometry in the 42 HCCs with high cell viability. 
GEP expression ranged from 0.4 to 34.3% (mean, 6.8%; 
median, 6.1%) (GEP+, %) in HCC tumor tissues, and 
was significantly higher than their paired adjacent non-
tumor liver counterparts (p < 0.001, n = 42) (Figure 1A). 
In addition, GEP levels were positively associated with 
venous infiltration (p = 0.030) (Table 1). The result 
corroborated with our previous observation that strong 
GEP expression by immunohistochemistry was associated 
with venous infiltration [11].
GEP was shown to co-express with stem cell 
markers in cell models [17]. Here, GEPhigh and GEPlow 
subpopulations were isolated from freshly resected HCC 
specimens. GEP is an autocrine and paracrine growth factor 
detectable both on the cell surface and intracellularly. The 
cells were sorted according to cell surface GEP, and not 
permeabilized for intracellular GEP, in order to maintain 
the cell viability for subsequent functional assays. Thus 
all cells in the GEPhigh subpopulation were positive for cell 
surface GEP. For the post-sorting analysis using a different 
antibody for detection, the cells were permeabilized and 
stained for intracellular GEP. Approximately 80-85% 
of GEPhigh cells expressed GEP, while about 10% was 
detected in the GEPlow subpopulation (Figure 1B).
The sorted cells were examined for their expression 
of stem cell markers using flow cytometry. GEPhigh cells 
isolated from clinical HCCs expressed significantly higher 
levels of hepatic CSC markers CD133, pluripotency-
associated signaling molecules β-catenin, Oct4, Nanog, 
SOX2 and ABC drug transporter ABCB5, than their GEPlow 
counterparts (Figure 1C). GEPhigh cells also expressed 
higher level of another hepatic marker EpCAM than 
GEPlow cells, although statistical significant difference has 
not been reached. The data is consistent with our previous 
findings that GEP preferentially co-expressed with stem 
cell markers in cell models [17].
GEPhigh cells possess CSC properties in vitro
To determine whether GEPhigh cells were enriched 
for CSCs, we compared the tumorigenic potential and 
stem cell properties of GEPhigh cells with their counterparts 
in vitro. Clonogenicity of the cells was assessed by 
colony formation assay. GEPhigh cells were able to form 
significantly more colonies compared with GEPlow cells 
(n = 6) (Figure 2A).
To assess the self-renewal ability, GEPhigh and GEPlow 
cells were allowed to grow as spheroids. Significantly greater 
number of spheroids were generated from GEPhigh cells 
than GEPlow counterpart (n = 3) (Figure 2B, 1° spheroids). 
Moreover, when GEPhigh cell-derived 1° spheroids were 
dissociated into desegregated cells, these cells could form 
second generations of spheroids (Figure 2B, 2° spheroids), 
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which were clonally expanded for at least 10 more 
generations thereafter. The results therefore demonstrated 
the unlimited growth potential and self-renewal ability of 
GEPhigh cells. Besides, it is noteworthy that GEP levels in the 
spheroids were higher than those in original resected tumors 
(Figure 2B, lower panel), implying that GEP was enriched in 
the spheroids and might play important role in maintaining 
the stemness of cells.
To determine the differentiation potential of these 
GEP-expressing cells, GEPhigh cell-derived 2° spheroids 
were dissociated and cultivated in the presence of serum 
but without growth factor supplements on adherent plate. 
After few days, the cells attached onto the plates and grew 
as adherent cells (Figure 2B, differentiated cells). As 
compared with spheroids, the differentiated and adherent 
counterparts expressed lower GEP level following the 
induced in vitro differentiation (Figure 2B, lower panel).
To examine the role of GEP in chemoresistance, 
cells were incubated with doxorubicin and assessed for 
intracellular drug accumulation. GEPhigh subpopulations 
demonstrated significantly lower doxorubicin retention 
when compared with the unsorted control and GEPlow 
subpopulations (n = 3) (Figure 2C).
GEPhigh cells are more tumorigenic in vivo
In vivo tumorigenicity assay using GEPhigh and 
GEPlow subpopulations isolated from HCC clinical speci-
mens were examined in immunocompromised NOD/
SCID mice. Cells isolated from 4 out of 11 HCC tumor 
specimens (36%) could generate xenograft tumors. Among 
these 4 cases, almost all mice injected with GEPhigh cells 
could generate visible tumors before 15 weeks post-
injection (Figure 3A and Table 2). As few as 1×103 GEPhigh 
Figure 1: GEP positive HCC cells express stem cell related molecules. Fresh HCC and paralleled non-tumor liver tissues were 
collected. After enzymatic digestion, cell viabilities were assessed by trypan blue staining, and only cases with high cell viability (viability 
≥ 70%) (n = 42/90, 47%) were subject to subsequent characterization. A. Cells isolated from fresh HCC and non-tumor tissues were stained 
for total cellular GEP and analyzed by flow cytometry (n = 42). B. Cells were sorted according to cell surface GEP. Sorted GEPhigh and 
GEPlow HCC cells were then permeabilized and stained for cellular GEP using anti-GEP antibody recognizing different epitope from that 
of the sorting antibody, and analyzed by flow cytometry. Percentage of GEP+ cells and mean fluorescence intensity (MFI) of the unsorted 
and sorted populations were shown. C. Sorted GEPhigh and GEPlow cells and unsorted control were stained for hepatic surface CSC markers 
CD133 and EpCAM, pluripotency-associated signaling molecules β-catenin, Oct4, Nanog and SOX2, and drug transporter ABCB5, and 
analyzed by flow cytometry (n > 7 for each marker). The lines in scatter plots indicated the median values.
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cells were able to generate visible tumors 8-15 weeks after 
injection. On the contrary, no tumor could be observed 
from GEPlow cells at all doses (Figure 3A and Table 2). 
Our result demonstrated that the cells capable of initiating 
HCC were highly enriched in GEPhigh subpopulation.
To demonstrate the in vivo self-renewal ability of 
the cells, xenografts growing from initial inoculation 
(1° xenografts) were serially transplanted into secondary 
mouse recipients. Only GEPhigh, but not GEPlow cells, could 
be successfully engrafted and form tumors (Table 3). Note 
that all mice injected with GEPhigh form tumors shortly 
after injection (4-10 weeks). The results indicated that 
GEPhigh cells in the tumor mass were able to generate serial 
xenografts, indicating the in vivo self-renewing capacity of 
GEP-expressing cells.
We characterized the primary (1°) and secondary (2°) 
xenograft tumors formed by GEPhigh cells, and revealed low 
levels of GEP expression (GEP+ population ranging from 
0.24- 9.80%) in the tumor bulks (Figure 3B). The fact that 
transplantation of GEPhigh cells could generate a heterogeneous 
tumor mass consisting of both GEP-positive and GEP-negative 
cells, demonstrated the self-renewal and differentiation ability 
of GEP-expressing cells in HCC (Figure 3B).
Association of GEP and β-catenin in clinical 
HCC specimens
Previously, we showed in HCC cell line models that 
GEP regulated the expression levels of hepatic CSC markers 
CD133 and EpCAM, pluripotency-associated signaling 
Table 1: HCC clinico-pathological features in relation to GEP levels
Clinico-pathological variables GEP^ P value
Low High
Age
 Young (≤60) 15 7 0.827
 Elderly (>60) 13 7
Venous infiltration
 Absent 11 1 0.030
 Present 17 13
HBV status
 Negative for HBsAg 6 4 0.608
 Positive for HBsAg 22 10
Cellular differentiation (Edmondson-Steiner grade)
 Well-differentiated 18 8 0.750
 Poorly-differentiated 9 5
Tumor stage (version UICC7)
 Early stage 15 5 0.418
 Late stage 10 6
Tumor size
 Small (≤5cm) 7 3 0.798
 Large (>5cm) 21 11
Serum AFP level
 Low (≤400 ng/ml) 13 8 0.513
 High (>400 ng/ml) 15 6
Number of tumor nodules
 Single 18 8 0.653
 Multiple (≥2) 10 6
^The cutoff for GEP expression levels was 6.92 (% of GEP+ cells), which was determined by maximizing the Youden index 
for the prediction of 1-year recurrence-free survival.
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molecules β-catenin, SOX2, Oct4 and Nanog at protein 
levels [17]. Here we studied the association between GEP 
and these molecules by RT-qPCR. Up-regulation of GEP 
levels elevated the transcript levels of CD133, β-catenin and 
SOX2, vice versa for suppression on GEP levels in HCC 
cell models (Supplementary Figure S1).
The transcript levels of GEP, CD133, β-catenin and 
SOX2 were further examined in clinical specimens. HCC 
tissues showed elevated expression of β-catenin when 
compared with their paralleled non-tumor liver tissues 
(n = 77, p < 0.001) and with the normal livers from healthy 
individuals (n = 10, p = 0.001) (Figure 4A). SOX2 also 
Figure 2: GEPhigh cells possess CSC properties in vitro. A. Sorted GEPhigh cells isolated from freshly resected HCC were able to 
form more colonies than GEPlow cells (n = 6). In brief, 1000 cells of each freshly sorted subpopulation were seeded onto 6-well plate and 
allowed to grow for a month. B. Upper panel: GEPhigh cells, but not GEPlow cells, isolated from freshly resected tumors were able to generate 
primary (1°) spheroids (n = 3). 1° spheroids were collected and dissociated, and 1000 disaggregated cells were allowed to grow for 1 month 
for generating secondary (2°) spheroids (n = 3). GEPhigh cell-derived, but not GEPlow cells-derived 1° spheroids, were able to generate 2° 
spheroids. Following induced differentiation, disaggregated cells generated from GEPhigh cell-derived 2° spheroids differentiated and grew 
as adherent cells. Lower panel: Flow cytometric analysis showed the enrichment of GEP expression in mechanically dissociated GEPhigh 
cells-derived spheroids as compared to the original resected tumors (clinical specimens) and the differentiated adherent counterpart. Briefly, 
1000 cells of each freshly sorted subpopulation were seeded into ultra-low attachment 24-well plate, and allowed to grow for 1 month to 
generate spheroids. C. After exposure to doxorubicin (0.5μg/ml) for 24h, GEPhigh cells retained significantly less doxorubicin than GEPlow 
cells and unsorted control (n = 3). Data are expressed as mean percentage + SD.
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showed higher transcript levels in HCC tissue than the 
non-tumors (n = 30, p = 0.045) (Supplementary Figure S2) 
with marginal difference on the mean and median levels. 
However, CD133 transcript levels were higher in non-
tumors than HCCs (n = 30, p < 0.001) (Supplementary 
Figure S2), which might be due to the contamination of 
CD133+ hematopoietic and endothelial progenitor cells [28, 
29]. Thus, the sample size for CD133 and SOX2 was not 
further increased to parallel the β-catenin full sample set.
Significant correlation between GEP and β-catenin 
expression was observed in HCC tumor tissues (n = 77, 
Spearman’s ρ correlation coefficient = 0.355, p = 0.002), 
paralleled non-tumor liver tissues (n = 77, Spearman’s ρ 
correlation coefficient = 0.599, p < 0.001), and tumor/ 
non-tumor (T/NT) ratio (n = 77, Spearman’s ρ correlation 
coefficient = 0.713; p < 0.001) (Figure 4B).
β-catenin expression and HCC clinico-
pathological features
The association of β-catenin transcript levels with 
clinico-pathological parameters in HCC patients (n = 77) 
were further examined. β-catenin levels were significantly 
associated with Edmondson-Steiner grade (Table 4; p = 
0.028). Here we showed that patients with high levels of 
β-catenin tended to have poor recurrence-free and overall 
Figure 3: GEPhigh cells possess CSC properties in vivo. GEPhigh and GEPlow cells were sorted from freshly resected tumors of HCC 
patients and injected into NOD/SCID mice. A. The upper panel shows the NOD/SCID mice injected subcutaneously with 1x 104 GEPhigh 
(right flank) and GEPlow (left flank) cells at 8-14 weeks after inoculation. Arrow indicated the site of tumor formation at the right flank of 
mice. The lower panel shows the corresponding subcutaneous tumors derived from GEPhigh cells. B. Flow cytometric analysis showed the 
total cellular GEP expression in mechanically dissociated GEPhigh cells derived-xenograft tumors (1° and 2°) as compared to the original 
clinical specimens. In brief, to demonstrate the in vivo self-renewal ability of the cells, GEPhigh and GEPlow subpopulations were sorted from 
xenografts growing from initial inoculation (1° xenografts) and then transplanted into secondary mouse recipients. GEPhigh, but not GEPlow 
subpopulations, were able to generate secondary (2°) xenograft tumors. Data are expressed as mean percentage + SD.
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Table 2: In vivo tumorigenicity of sorted GEPhigh and GEPlow subpopulations from clinical HCC specimens
Case no. Sorted cells^ Cell no. injected Tumor incidence Latency (weeks)
40 GEPhigh 1×10^5 3/3 4, 5, 5
1×10^4 3/3 5, 5, 5
1×10^3 4/4 8, 11, 15, 15
GEPlow 1×10^5 0/3 >20, >20, >20
1×10^4 0/3 >20, >20, >20
1×10^3 0/4 >20, >20, >20, >20
50 GEPhigh 1×10^5 3/3 6, 6, 7
1×10^4 3/3 8, 10, 10
1×10^3 4/4 8, 12, 13, 13
GEPlow 1×10^5 0/3 >20, >20, >20
1×10^4 0/3 >20, >20, >20
1×10^3 0/4 >20, >20, >20, >20
52 GEPhigh 1×10^4 2/2 8, 10
1×10^3 2/2 9, 14
GEPlow 1×10^4 0/2 >20, >20
1×10^3 0/2 >20, >20
53 GEPhigh 1×10^5 2/2 6, 8
1×10^4 1/2 6, >20
1×10^3 0/2 >20, >20
GEPlow 1×10^5 0/2 >20, >20
1×10^4 0/2 >20, >20
1×10^3 0/2 >20, >20
^Sorted cell populations from clinical HCC specimens.
Table 3: Serial transplantation of GEPhigh cells-derived xenografts
Case no. Sorted cells^ Tumor incidence Latency (weeks)
40 GEPhigh 2/2 4, 5
GEPlow 0/2 >20, >20
50 GEPhigh 2/2 8, 10
GEPlow 0/2 >20, >20
52 GEPhigh 2/2 9, 9
GEPlow 0/2 >20, >20
53 GEPhigh 2/2 4, 5
GEPlow 0/2 >20, >20
^Sorted cell populations from GEPhigh cells-derived xenografts and cell number per injection was 1×10^4.
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survival, although statistical significance was not reached 
(log-rank test, p = 0.053 and p = 0.128, respectively) 
(Figure 4C and Supplementary Figure S3). GEP expression 
levels have been shown to associate with recurrence 
[13], therefore β-catenin and GEP levels were assessed 
together to investigate if this could add incremental 
prognostic information for HCC patients. The patients 
were segregated into two groups, the low expression group 
(low in either one or both GEP and β-catenin levels) and 
the high expression group (high in both GEP and β-catenin 
levels). There were 61 patients in the low expression group 
(median recurrence-free survival, 24.5 months) and 16 
patients in the high expression group (median recurrence-
free survival, 12.6 months). Notably, high GEP and 
β-catenin levels were significantly associated with poor 
recurrence-free survival (log-rank test, p = 0.038). When 
the patients were segregated into early and late tumor 
stages, patients with high GEP and β-catenin levels were 
Figure 4: Clinical significance of GEP and β-catenin in HCC clinical specimens. A. β-catenin transcript level was significantly 
up-regulated in HCC tumor (HCC, n = 77) compared with the paralleled tumor-adjacent non-tumor liver tissues (non-tumor, n = 77) and 
normal livers from healthy individuals (normal, n = 10). The lines indicate the median values. B. Expression levels of GEP significantly 
correlated with that of β-catenin in HCC tumor tissues (HCC), and in the paralleled non-tumor tissues. The tumor / non-tumor (T/NT) ratio 
showed the same trend. C. Kaplan–Meier recurrence-free survival plot according to β-catenin levels (log-rank test, p = 0.053). There were 56 
patients with low β-catenin expression and 21 patients with high β-catenin expression (median recurrence-free survival of 24.5 months and 
12.8 months, respectively). D. Patients (n = 77) were segregated into the low expression group (either one or both low in GEP and β-catenin) 
and the high expression group (both high in GEP and β-catenin). There were 61 patients in the low expression group (median recurrence-free 
survival, 24.5 months) and 16 patients in the high expression group (median recurrence-free survival, 12.6 months). Patients with high GEP 
and β-catenin levels were found to have poor recurrence-free survival (log-rank test, p = 0.038). When the patients were segregated into early 
and late tumor stages, patients with high GEP and β-catenin levels also demonstrated poor recurrence-free survival (log-rank test, p = 0.022).
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also found to have poor recurrence-free survival in both 
subgroups (log-rank test, p = 0.022) (Figure 4D).
To examine the prediction power for recurrence-free 
survival, Cox regression analysis was used to compare the 
GEP and β-catenin levels with tumor stage. By univariable 
Cox regression analysis, high expression levels of GEP and 
β-catenin [hazard ratio (HR), 1.9; 95% confidence interval 
(CI), 1.0–3.7; p = 0.041] and late tumor stage (HR, 1.9; 
95% CI, 1.1–3.4; p = 0.028) were significantly associated 
with poor recurrence-free survival. By multivariable Cox 
regression analysis, both GEP and β-catenin (HR, 2.2; 95% 
CI, 1.1–4.2; p = 0.019), and late tumor stage (HR, 2.1; 
95% CI, 1.2–3.7; p = 0.014), were independent prognostic 
factors for recurrence-free survival (Table 5). The above 
findings demonstrated that high GEP and β-catenin levels 
significantly influenced the prognosis of HCC patients who 
underwent curative partial hepatectomy.
DISCUSSION
In this study, we have confirmed the role of GEP in 
hepatic CSCs in HCC clinical specimens. The present work 
further established GEP as CSC marker and conferred 
biological function on enrichment of CSC properties 
including spheroid formation and the ability to form tumor 
with minimal cell load by GEP positive HCCs directly 
isolated from clinical specimens. GEP was shown to tightly 
associate with β-catenin levels in HCC clinical specimens. 
Furthermore, HCC patients with high GEP and β-catenin 
expression levels demonstrated poor recurrence-free survival.
Table 4: Clinico-pathological features of HCC in relation to β-catenin transcript level
Clinico-pathological features β-catenin^ P value
Low High
Age
 Young (≤60) 39 15 0.879
 Elderly (>60) 17 6
Venous infiltration
 Absent 29 8 0.284
 Present 27 13
HBV status
 Negative for HBsAg 7 5 0.236
 Positive for HBsAg 48 16
Cellular differentiation 
 (Edmondson-Steiner grade)
 Well-differentiated 51 15 0.028
 Poorly-differentiated 5 6
Tumor stage (version UICC7)
 Early stages 36 15 0.555
 Late stages 20 6
Tumor size
 Small (≤5cm) 14 4 0.583
 Large (>5cm) 42 17
Serum AFP level
 Low (≤400ng/ml) 37 10 0.139
 High (>400ng/ml) 19 11
Number of tumor nodules
 Single 39 17 0.321
 Multiple (≥2) 17 4
^The cutoff for β-catenin was 12.46, which was the mean value of β-catenin transcript level in HCC.
Oncotarget21653www.impactjournals.com/oncotarget
The protein levels of GEP and a panel of stem cell 
related markers in freshly resected HCC specimens were 
investigated in the present study. The isolated cells were 
examined for viability, and revealed that the HCC specimens 
that generated cells with high viability were significantly 
associated with presence of venous infiltration and poor 
differentiation, which were aggressive HCC features. GEP 
levels (by flow cytometry) were positively associated with 
venous infiltration in the current HCC cohort, which further 
corroborated our previous report that GEP regulated HCC 
cell invasion ability and that strong GEP expression (by 
immunohistochemistry) associated with venous infiltration 
[11]. Noted that the percentage of GEP+ cells was higher 
than previously described [17], which may be due to the 
exclusion of cases with low viability. In fact, we previously 
reported that GEP protected HCC cells from anoikis-
induced apoptosis and GEP levels significantly correlated 
with the viability of isolated HCCs in single-cell suspension 
[28]. Therefore, GEP expression empowered the HCC cells 
to sustain high viability, and vice versa HCCs with high 
viability showed high GEP expression. Thus, GEP over-
expression contributed to the HCC aggressive feature in 
particular invasion ability and cell viability in detachment 
which are essential properties for cancer metastasis.
In addition, we showed that β-catenin transcript 
levels in HCC specimens were significantly associated 
with cellular differentiation by Edmondson-Steiner grade. 
Our result echoes the report by other researchers that 
β-catenin was significantly higher than its non-tumor 
counterparts, and the increased expression was correlated 
with Edmondson-Steiner grade [30]. Poorly-differentiated 
tumors generally exhibited poor prognoses. It was found 
that poorly-differentiated tumors displayed over-expression 
of genes that were normally enriched in embryonic stem 
cells [31]. Moreover, expressions of Oct4, SOX2, Nanog 
and c-Myc were observed more frequently in poorly-
differentiated tumors than in well-differentiated tumors. 
Such embryonic stem cell signature was also present in 
poorly differentiated glioblastomas and bladder carcinomas 
[31]. Here, patients with high levels of β-catenin showed 
poor recurrence-free survival, though statistical significance 
had not been reached (p = 0.053), which might probably 
due to small sample size. However, when combining GEP 
and β-catenin, it was demonstrated that HCC patients with 
high GEP and β-catenin levels had significantly poorer 
recurrence-free survival than the low expression group 
(log-rank test, p = 0.038). The result suggested the effect 
of GEP and β-catenin by regulating the stemness and 
invasiveness of tumors for prediction of HCC prognosis.
Activation of β-catenin in HCC induces the expressions 
of genes encoding for cyclin D1, survivin, c-Myc, EpCAM, 
and VEGF-A, which contribute to HCC by regulating cell 
proliferation, survival, metabolism and angiogenesis [32, 33]. 
Dysregulation of the Wnt/β-catenin was reported to cause 
transformation of liver stem/progenitor cells, implying a role 
in self-renewal of hepatic stem cells [34]. Thus, inhibition 
of β-catenin in a subset of HCC should have significant 
therapeutic relevance. The small molecule FH535 was 
shown to prevent Wnt-mediated signaling by suppressing 
the recruitment of β-catenin co-activators to target gene 
promoters in HCC cell line model [35]. The expression of 
cyclin D1 and survivin, the two well-characterized targets of 
β-catenin, was found to be reduced by FH535 [36]. Besides, 
it was also illustrated that interferon could inhibit β-catenin 
signaling by upregulating RanBP3, a nuclear export factor for 
extruding β-catenin outside the nucleus [37]. However, these 
molecules were not tested in clinical trials yet, and could be 
target for therapeutic development in HCC patients.
In addition to GEP and β-catenin, expression of 
CD90/EpCAM have also been reported in HCC samples, 
however, with controversial clinical implications 
[38–41]. CD90 was shown to express in inflamed and 
normal liver tissues but not exclusively in HCC [38]. 
In HCC tissues, CD90 was observed on endothelial 
cells, leukocytes, stroma and also tumor cells [39]. 
Therefore, additional markers such as CD45 and CD31 
would be needed to distinguish the expression of CD90 
in hepatic cells from the other cell types. Biological 
role of EpCAM in carcinogenesis was contentious [40]. 
EpCAM overexpression was associated with protective 
Table 5: Cox regression analyses for recurrence-free survival on GEP/β-catenin levels and tumor stage
Variables^ n Univariable analysis Multivariable analysis




 Low 61 1.0 1
 High 16 1.9 (1.0-3.7) 0.041 2.2 (1.1-4.2) 0.019
Tumor stage
 Early 51 1.0 1
 Late 26 1.9 (1.1-3.4) 0.028 2.1 (1.2-3.7) 0.014
^GEP and β-catenin levels examined by real-time RT-PCR were modeled as categorical variables in the analyses.
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or promoting roles in patients with different cancer types 
[40]. In the current study, EpCAM expression levels varied 
greatly among individual patients, ranging from 39.2 to 
86.3% HCC cells that expressed EpCAM on their surfaces 
(Figure 1C, EpCAM unsorted cells). Other research group 
has also reported similar EpCAM expression levels in 
HCC [41]. Notably, such high proportion of EpCAM+ 
cells would be doubtful to serve as specific CSC marker. 
Therefore, additional marker such as AFP would be 
necessary to co-stain with EpCAM to further delineate the 
specific EpCAM+ hepatic CSCs [9]. Further effort would 
be needed to comprehensively examine these markers.
GEP blockage by antibody approach could sensitize 
HCCs to conventional therapies including chemotherapy 
[16]. Our group previously demonstrated in HCC cell 
line models that GEP modulated pluripotency-associated 
signaling molecules including β-catenin and SOX2 [17]. 
Here, we showed that GEP was significantly associated 
with β-catenin and poor clinical outcome in HCC patients. 
Therefore, GEP might contribute to hepatic CSC properties 
by regulating pluripotency-associated signaling molecules. 
Targeting GEP might represent a potential therapeutic 
strategy to reduce the stemness of CSCs. Further 
investigations are warranted to investigate the combination 
therapeutic approach for treatment of the aggressive HCCs.
MATERIALS AND METHODS
Clinical specimens
The study protocol was approved by the Institutional 
Review Board of the University of Hong Kong / Hospital 
Authority Hong Kong West Cluster (HKU/HA HKW 
IRB). Patients underwent surgical resection for HCC 
between 2010 and 2014 at Queen Mary Hospital, Hong 
Kong, were prospectively recruited with written informed 
consent. Note that all patients were intended to receive 
curative resection and therefore extra-hepatic metastasis 
were only incidental events. Totally 3 out of 90 patients 
were observed to have extrahepatic diseases at the time 
of surgery. TOCE/TACE before surgery was performed 
in 5 out of 90 patients. The mean follow-up period was 
19.0 months, while median was 18.2 months. Tumor and 
adjacent non-tumor liver tissue pairs from HCC patients 
(n=90) were freshly collected, sliced and digested by type 
IV collagenase (Sigma-Aldrich, St. Louis, MO). After 
filtration through 40 micron-cell strainer (BD Biosciences, 
San Jose, CA) and lysis of red blood cells, cells were 
counted and assessed for viability by trypan blue staining. 
Only cases with cell viability ≥ 70% (n = 42) were subject 
to phenotypic characterization, cell sorting and functional 
assays in the current study. The present data on CD133, 
EpCAM, β-catenin, Oct4, Nanog, SOX2 and ABCB5 
on sorted cell populations were new data, while part of 
the GEP data have been reported in our previous studies 
[17, 18, 42, 43] and the current study has increased 
sample size to parallel datasets on stem-cell related 
molecules. Note that each clinical specimen generated 
only limited number of cells for subsequent experiments, 
and therefore not enough for comprehensive examination 
on the full panel of stem cell markers or functional assays. 
For the stem cell marker investigation, at least 7 clinical 
specimens were examined. For cancer stem cell properties, 
at least 3 HCCs were investigated in the functional assays. 
Details have been described in the result section.
For clinico-pathological association and survival 
analyses on GEP, β-catenin, CD133 and SOX2, the 
retrospective clinical cohort were HCC patients who 
underwent surgical resection for HCC between 2002 and 
2005 at Queen Mary Hospital, Hong Kong. All patients 
were intended to receive curative resection and extra-
hepatic metastasis were incidental findings in three patients 
at the time of surgery. No patient in this cohort received 
TOCE/TACE before surgery. The mean follow-up period 
was 107.4 months and median 109.5 months. Tumor and 
adjacent non-tumor tissue pairs from HCC patients (n = 
77) were collected and total RNA was extracted from snap 
frozen tissue specimens for transcript level analysis using 
real-time quantitative RT-PCR as previously described [13, 
15]. The The β-catenin, CD133 and SOX2 data presented 
were new data, whereas the GEP data had been extracted 
from the previous reported cohorts [13, 18] for studying 
paralleled datasets on β-catenin, CD133 and SOX2.
Immunofluorescence staining and flow 
cytometric analysis
For expressions of GEP, β-catenin, Oct4, SOX2, Nanog 
and ABCB5, cells were permeabilized with ice-cold 0.1% 
saponin and then incubated with FITC-conjugated mouse anti-
human GEP (Versitech Ltd., [14]), Alexa Fluor 647-conjugated 
mouse anti-human β-catenin, PerCP-Cy5.5-conjugated 
mouse anti-human Oct4, Alexa Fluor 647-conjugated mouse 
anti-SOX2, PE-conjugated mouse anti-human Nanog 
(BD Biosciences), unconjugated goat anti-human ABCB5 
(Everest Biotech Ltd, Oxfordshire, UK), or equal amount 
of corresponding isotype controls. For ABCB5, cells were 
incubated with NorthernLights (NL) 557-conjugated donkey 
anti-goat IgG secondary antibody after primary antibody. For 
CD133 and EpCAM surface expression, cells were stained 
with APC-conjugated mouse anti-human CD133 (Miltenyi 
Biotec, Bergisch Gladbach, Germany), APC-conjugated mouse 
anti-human EpCAM (BD Biosciences) or equal amount of 
corresponding isotype controls.
Real-Time quantitative reverse-transcription 
polymerase chain reaction
Real-time quantitative RT-PCR was performed as 
described previously [11]. Quantification was performed 
with the ABI Prism 7700 sequence detection system 
(Applied Biosystems, Foster City, CA). Primers and probe 
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for GEP have previously been described [11]. Primers 
and probe were ready-made reagents (Pre-Developed 
TaqMan Assay Reagents; Applied Biosystems) for 
CD133, EpCAM, ABCB5, SOX2, Oct4, β-cat and Nanog 
(catalog no./assay ID: Hs01009250_m1, Hs00901885_
m1, Hs00698751_m1, Hs01053049_s1, Hs01895061_u1, 
Hs00355049_m1 and Hs02387400_g1, respectively), 
and 18S rRNA internal control. In brief, there were 40 
amplification cycles. The sample was regarded as absent 
for expression when there was no detectable signal up 
to 40 cycles. The relative amount of the above markers 
had been normalized with control 18S for RNA amount 
variation and calibrator for plate-to-plate variation, and the 
results were presented as the relative fold change.
Cell sorting
Isolation of GEP-expressing cells was performed by 
magnetic activated cell sorting (Miltenyi Biotec) according 
to manufacturer’s instructions. Briefly, cells were stained 
with FITC-conjugated mouse anti-human GEP (Versitech 
Ltd., [14]), and then incubated with anti-FITC magnetic 
microbeads (Miltenyi Biotec), prior to magnetic separation. 
Cells were sorted based on the surface expression of GEP, but 
not on their intracellular expression, because permeabilization 
was avoided to keep the cells viable for subsequent functional 
assays. After cell isolation, sorted cells were assessed for cell 
viability by trypan blue staining and total cellular GEP levels 
by flow cytometry using mouse anti-human GEP (R&D 
systems, Minneapolis, MN) antibody recognizing different 
GEP epitope. Sorted cells were permeabilised prior to 
staining so that total GEP expression of the sorted cells could 
be determined. Cells were then stained with PE-conjugated 
rabbit anti-mouse secondary antibody. Post-sorting analysis 
consistently indicated purities >80% with minimal cell death.
Colony formation assay
Freshly isolated cells were seeded at a density of 
1000 cells per 6-well and allowed to grow for a month. 
Colony formation was assessed by a colorimetric assay 
using crystal violet (Sigma Aldrich).
Spheroid formation assay
Cells were seeded to grow as spheroids in non-adherent, 
serum-free and growth factor-supplemented conditions that 
favor the proliferation of undifferentiated cells. Disaggregated 
1000 cells were cultured in 500 μl of serum-free DMEM/
F12 medium (ThermoFisher Scientific Ltd., Waltham, MA), 
supplemented with 20 ng/ml human recombinant EGF (Sigma 
Aldrich), 10 ng/ml human recombinant bFGF (ThermoFisher 
Scientific), 4 μg/ml insulin (Sigma Aldrich), B27 (1: 50; 
ThermoFisher Scientific). Cells were cultured in ultra-low 
attachment 24-well plate (Sigma Aldrich). Cells were cultured 
for 1 month and replenished with 100 μl of supplemented 
medium every 2-3 days. After 1 month, primary (1°) spheroids 
were collected, counted, and dissociated to disaggregated 
cells by trypsin. 1000 disaggregated cells were allowed to 
grow in DMEM/F12 medium with the above growth factors 
and supplements for another 1 month for the generation of 
secondary (2°) spheroids. The 2° spheroids formed after 
1 month were then collected, counted and passaged as above 
mentioned for over 10 generations thereafter.
For epithelial in vitro cell differentiation, a few 
2° spheroids were dissociated into disaggregated cells 
and seeded onto 6-well plate in DMEM/F12 medium 
supplemented with 10% FBS without the above mentioned 
growth factors and supplements.
Doxorubicin accumulation
Cells were incubated with or without 0.5 μg/ml 
doxorubicin for 24h, prior to washing with PBS once. 
Doxorubicin has intrinsic fluorescence (emission 
wavelength: 580 nm) and the intracellular doxorubicin 
level of the cells was detected by flow cytometry at FL2 
spectrum as described previously [13, 17, 44].
In vivo tumorigenicity experiments
The study protocol was approved by the Committee 
on the Use of Live Animals in Teaching and Research at the 
University of Hong Kong. NOD/SCID mice of 5-8 weeks old 
were used to assess the in vivo tumorigenic potential of the 
cells. Various cell numbers (1×103 to 1×105) were mixed with 
Matrigel (BD Biosciences) and inoculated subcutaneously 
at the dorsal region of the trunk of each animal. Mice were 
sacrificed between 8 and 20 weeks post-injection, at which 
tumors were harvested for further investigation. Those mice 
injected with tumor cells but showed no sign of tumor burden 
were terminated 4-5 months after cell injection.
Cell culture and GEP transfection
Human HCC cell lines, Hep3B and HepG2, were 
purchased from the American Type Culture Collection. 
Stable transfectants for GEP overexpression was 
established by transfecting GEP full-length (FL) cDNA 
into HepG2, a cell line with low endogenous GEP level; 
while GEP suppression was performed by transfecting 
GEP shRNA (sh) into Hep3B, a cell line with high 
endogenous GEP level [11]. All transfectants were 
maintained in 10% advanced minimum essential media 
(AMEM) with 0.4 mg/mL of G418.
Statistical analyzes
All analyzes were performed using the statistical 
software GraphPad Prism Version 6.00 for Windows 
(GraphPad Software, CA, USA) or SPSS version 16.0 
for Windows (SPSS Inc, Chicago, IL). All in vitro data 
were expressed as mean values ± standard deviation (SD) 
from at least three independent experiments. Continuous 
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variables were assessed by Spearman correlation and 
compared between groups by ANOVA (clinical samples) 
or Student t test (in vitro models). GEP and β-catenin 
transcript levels were continuous variables, and the 
data were modeled as categorical variables in Kaplan–
Meier and Cox regression analyses. Mean, median or 
Youden index (i.e., sensitivity + specificity − 1) had 
been considered and used to determine the optimal 
cutoff values for the prediction of 1-year or 3-year 
recurrence-free survival. The cutoff value for GEP protein 
expression levels in viable cells isolated from fresh 
HCC specimens (n = 42) was 6.92% (% of GEP+ cells), 
which was determined by Youden Index for prediction of 
1-yr recurrence-free survival. The cutoff value for GEP 
transcript levels in archived HCC specimens (n = 77) was 
5.83 (relative GEP mRNA levels), which was determined 
by Youden Index for prediction of 3-yr recurrence-free 
survival. For β-catenin transcript levels in archived HCC 
specimens, the cutoff value was 12.46, which was the 
mean value. The association of GEP, β-catenin and tumor 
stage (Union Internationale Contre le Cancer version 7, 
UICC7) with recurrence-free survival was examined by 
univariable and multivariable Cox proportional hazards 
regression with a forward stepwise selection procedure. 
A probability (p) < 0.05 was considered significantly 
different.
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